Prostatic Neoplasms: all 6,484 studies

Page 65 of 65. Open to participants first (1,415), then studies with results posted, then the rest; newest registration first within each.

• Vaccine Therapy in Treating Patients With Metastatic Prostate CancerCompletedNCT00004211Phase 1/2
• Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone TherapyCompletedNCT00004149Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate CancerCompletedNCT00004071Phase 2/3
• Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic CancerCompletedNCT00004065Phase 1
• Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate CancerTerminatedNCT00004050Phase 2
• Chemotherapy in Treating Patients With Prostate CancerCompletedNCT00004045Phase 2
• Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate CancerCompletedNCT00004043Phase 2
• Vaccine Therapy in Treating Patients With Metastatic Prostate CancerCompletedNCT00004029Phase 1
• CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous TherapyTerminatedNCT00004026Phase 2
• Liposomal Doxorubicin in Treating Patients With Prostate CancerCompletedNCT00004014Phase 2
• S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00004001Phase 3
• Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate CancerCompletedNCT00003903Not applicable
• PSA Vaccine Therapy in Treating Patients With Advanced Prostate CancerCompletedNCT00003871Phase 2
• Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for RecurrenceWithdrawnNCT00003858Phase 2
• Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate CancerCompletedNCT00003832Phase 2
• Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate CancerCompletedNCT00003819Phase 1
• Docetaxel in Treating Patients With Stage IV Prostate CancerCompletedNCT00003781Phase 2
• Trastuzumab in Treating Patients With Prostate CancerCompletedNCT00003740Phase 2
• Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate CancerStatus unknownNCT00003734Phase 3
• Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate CancerStatus unknownNCT00003717Phase 2
• Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00003690Phase 1
• Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate CancerTerminatedNCT00003682Phase 3
• Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate CancerCompletedNCT00003674Phase 3
• Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate CancerCompletedNCT00003653Phase 3
• Combination Chemotherapy in Treating Patients With Advanced Prostate CancerStatus unknownNCT00003633Phase 1
• Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone TherapyCompletedNCT00003626Phase 2
• Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone TherapyWithdrawnNCT00003622Phase 2
• Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate CancerCompletedNCT00003614Phase 2
• Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate CancerCompletedNCT00003607Phase 3
• Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate CancerWithdrawnNCT00003534Phase 2
• Antineoplaston Therapy in Treating Patients With Metastatic Prostate CancerTerminatedNCT00003533Phase 2
• Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate CancerWithdrawnNCT00003517Phase 2
• Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate CancerTerminatedNCT00003516Phase 2
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate CancerCompletedNCT00003400Phase 2
• Combination Chemotherapy in Treating Patients With Advanced Prostate CancerCompletedNCT00003394Phase 1/2
• Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00003391Phase 1
• Diet and PSA Levels in Patients With Prostate CancerCompletedNCT00003367Phase 3
• Chemotherapy in Treating Patients Who Have Metastatic Prostate CancerCompletedNCT00003343Phase 3
• Identification of Genes Associated With Cancer in Patients and Siblings Who Have CancerCompletedNCT00003329
• Hormone Therapy in Treating Patients With Prostate CancerCompletedNCT00003323Phase 2
• Brachytherapy in Treating Patients With Prostate CancerCompletedNCT00003312Phase 2
• Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate CancerCompletedNCT00003307Phase 2
• Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00003290Phase 3
• Vinorelbine in Treating Patients With Metastatic Prostate CancerCompletedNCT00003259Phase 2
• Flavopiridol in Treating Patients With Recurrent Prostate CancerCompletedNCT00003256Phase 2
• Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00003238Phase 2
• Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate CancerCompletedNCT00003232Phase 3
• Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate CancerStatus unknownNCT00003183Phase 1/2
• Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate CancerCompletedNCT00003162Phase 3
• Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00003124Phase 2
• Epidural Hydromorphone Compared With Hydromorphone Infusion in Treating Patients With Prostate Cancer Undergoing Radical ProstatectomyCompletedNCT00003115Phase 3
• Computer Planned Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00003104Phase 2
• Chemotherapy in Treating Patients With Solid TumorsCompletedNCT00003103Phase 1/2
• Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate CancerCompletedNCT00003084Phase 2
• Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate CancerCompletedNCT00003045Not applicable
• Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid TumorsCompletedNCT00003038Phase 1
• Hormone Therapy in Treating Patients With Advanced Prostate CancerCompletedNCT00003026Phase 3
• Surgery in Treating Patients With Prostate CancerCompletedNCT00002938Phase 2
• Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone TherapyCompletedNCT00002924
• Radiation Therapy With Androgen Suppression in Treating Patients With Prostate CancerCompletedNCT00002889Phase 2
• Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate CancerCompletedNCT00002881Phase 3
• Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate CancerCompletedNCT00002855Phase 3
• Group Therapy Compared With Educational Materials in Patients With Prostate CancerCompletedNCT00002848Not applicable
• Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate CancerStatus unknownNCT00002775Phase 1/2
• Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate CancerCompletedNCT00002760Phase 3
• Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate CancerCompletedNCT00002723Phase 3
• Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate CancerCompletedNCT00002721Phase 1
• Radiation Therapy in Treating Patients With Stage I or Stage II Prostate CancerCompletedNCT00002703Phase 3
• Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid TumorsCompletedNCT00002677Phase 1
• Pain Control in Patients With Recurrent or Metastatic Breast or Prostate CancerTerminatedNCT00002668Not applicable
• Biological Therapy in Treating Patients With Prostate CancerCompletedNCT00002637Phase 1/2
• Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00002633Phase 3
• Radiation Therapy in Treating Patients With Stage II or Stage III Prostate CancerCompletedNCT00002602Phase 1/2
• Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage CancerCompletedNCT00002520Not applicable
• Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate CancerCompletedNCT00002511Phase 3
• Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone MetastasesCompletedNCT00002503Phase 3
• Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00002480Phase 1
• Genetic Analysis of Hereditary Prostate CancerCompletedNCT00001469
• A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate CancerCompletedNCT00001446Phase 2
• A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory NeoplasmsCompletedNCT00001444Phase 1
• A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the ProstateCompletedNCT00001382Phase 1
• Familial Prostate CancerCompletedNCT00001377
• A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate CarcinomaCompletedNCT00001266Phase 2

← Prostatic Neoplasms overview